Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 244

1.

Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer.

Laheurte C, Dosset M, Vernerey D, Boullerot L, Gaugler B, Gravelin E, Kaulek V, Jacquin M, Cuche L, Eberst G, Jacoulet P, Fabre E, Le Pimpec-Barthes F, Tartour E, De Carvalho Bittencourt M, Westeel V, Adotévi O.

Br J Cancer. 2019 Aug;121(5):405-416. doi: 10.1038/s41416-019-0531-5. Epub 2019 Jul 30.

2.

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance.

Pernot S, Terme M, Radosevic-Robin N, Castan F, Badoual C, Marcheteau E, Penault-Llorca F, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Baptiste Bachet J, Borg C, Boige V, Voron T, Stanbury T, Tartour E, Gourgou S, Malka D, Taieb J.

Gastric Cancer. 2019 Jul 2. doi: 10.1007/s10120-019-00983-3. [Epub ahead of print]

PMID:
31267360
3.

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis.

Outh-Gauer S, Augustin J, Mandavit M, Grard O, Denize T, Nervo M, Lépine C, Rassy M, Tartour E, Badoual C.

J Vis Exp. 2019 Jun 14;(148). doi: 10.3791/59422.

PMID:
31259898
4.

Editorial: Tissue Resident Memory T Cells.

Mami-Chouaib F, Tartour E.

Front Immunol. 2019 May 27;10:1018. doi: 10.3389/fimmu.2019.01018. eCollection 2019. No abstract available.

5.

TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.

Fucikova J, Rakova J, Hensler M, Kasikova L, Belicova L, Hladikova K, Truxova I, Skapa P, Laco J, Pecen L, Praznovec I, Halaska MJ, Brtnicky T, Kodet R, Fialova A, Pineau J, Gey A, Tartour E, Ryska A, Galluzzi L, Spisek R.

Clin Cancer Res. 2019 Aug 1;25(15):4820-4831. doi: 10.1158/1078-0432.CCR-18-4175. Epub 2019 May 10.

PMID:
31076549
6.

Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer.

Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, Senovilla L, Bezu L, Vacchelli E, Sica V, Melis A, Martin T, Xia L, Yang H, Li Q, Chen J, Durand S, Aprahamian F, Lefevre D, Broutin S, Paci A, Bongers A, Minard-Colin V, Tartour E, Zitvogel L, Apetoh L, Ma Y, Pittet MJ, Kepp O, Kroemer G.

Nat Commun. 2019 Apr 17;10(1):1883. doi: 10.1038/s41467-019-09838-y.

7.

Crizotinib-induced immunogenic cell death in non-small cell lung cancer.

Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, Senovilla L, Bezu L, Vacchelli E, Sica V, Melis A, Martin T, Xia L, Yang H, Li Q, Chen J, Durand S, Aprahamian F, Lefevre D, Broutin S, Paci A, Bongers A, Minard-Colin V, Tartour E, Zitvogel L, Apetoh L, Ma Y, Pittet MJ, Kepp O, Kroemer G.

Nat Commun. 2019 Apr 2;10(1):1486. doi: 10.1038/s41467-019-09415-3. Erratum in: Nat Commun. 2019 Apr 17;10(1):1883.

8.

Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients.

Quillien V, Carpentier AF, Gey A, Avril T, Tartour E, Sejalon F, Campillo-Gimenez B, Vauleon E.

Cancer Immunol Immunother. 2019 Jun;68(6):871-882. doi: 10.1007/s00262-019-02317-9. Epub 2019 Mar 4.

9.

Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer-Just About Ready for Prime-Time?

Hofman P, Badoual C, Henderson F, Berland L, Hamila M, Long-Mira E, Lassalle S, Roussel H, Hofman V, Tartour E, Ilié M.

Cancers (Basel). 2019 Feb 27;11(3). pii: E283. doi: 10.3390/cancers11030283. Review.

10.

Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours.

Durgeau A, Virk Y, Gros G, Voilin E, Corgnac S, Djenidi F, Salmon J, Adam J, de Montpréville V, Validire P, Ferrone S, Chouaib S, Eggermont A, Soria JC, Lemonnier F, Tartour E, Chaput N, Besse B, Mami-Chouaib F.

Nat Commun. 2018 Nov 30;9(1):5097. doi: 10.1038/s41467-018-07603-1.

11.

High Therapeutic Efficacy of a New Survivin LSP-Cancer Vaccine Containing CD4+ and CD8+ T-Cell Epitopes.

Onodi F, Maherzi-Mechalikh C, Mougel A, Ben Hamouda N, Taboas C, Gueugnon F, Tran T, Nozach H, Marcon E, Gey A, Terme M, Bouzidi A, Maillere B, Kerzerho J, Tartour E, Tanchot C.

Front Oncol. 2018 Nov 13;8:517. doi: 10.3389/fonc.2018.00517. eCollection 2018.

12.

[Efficacy and toxicity of immune checkpoint inhibitors in elderly patients - 5th edition of the congress of pharmacology of anticancer drugs].

Gaultier De Saint Basile H, Poisson C, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Tartour E, De Guillebon E.

Bull Cancer. 2018 Dec;105(12):1202-1208. doi: 10.1016/j.bulcan.2018.10.004. Epub 2018 Nov 22. French.

PMID:
30471959
13.

Analytical validation of an alternative method to quantify specific antibodies in 3 applications.

Senant M, Bordereau P, Tartour E, Dragon-Durey MA.

J Immunol Methods. 2019 Jan;464:40-46. doi: 10.1016/j.jim.2018.10.008. Epub 2018 Oct 18.

PMID:
30342009
14.

Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy.

Beziaud L, Boullerot L, Tran T, Mansi L, Marie-Joseph EL, Ravel P, Johannes L, Bayry J, Tartour E, Adotévi O.

Int J Cancer. 2018 Dec 1;143(11):3008-3018. doi: 10.1002/ijc.31842. Epub 2018 Oct 1.

PMID:
30183073
15.

Resident memory T cells, critical components in tumor immunology.

Mami-Chouaib F, Blanc C, Corgnac S, Hans S, Malenica I, Granier C, Tihy I, Tartour E.

J Immunother Cancer. 2018 Sep 4;6(1):87. doi: 10.1186/s40425-018-0399-6. Review.

16.

Targeting Resident Memory T Cells for Cancer Immunotherapy.

Blanc C, Hans S, Tran T, Granier C, Saldman A, Anson M, Oudard S, Tartour E.

Front Immunol. 2018 Jul 27;9:1722. doi: 10.3389/fimmu.2018.01722. eCollection 2018. Review.

17.

Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.

Mauge L, Mejean A, Fournier L, Pereira H, Etienne-Grimaldi MC, Levionnois E, Caty A, Abadie-Lacourtoisie S, Culine S, Le Moulec S, Linassier C, Théodore C, Ravaud A, Albiges L, Grine A, Tartour E, Milano G, Gille AS, Verkarre V, Helley D, Oudard S; PREINSUT study group.

Clin Cancer Res. 2018 Nov 15;24(22):5534-5542. doi: 10.1158/1078-0432.CCR-18-1045. Epub 2018 Jul 30.

PMID:
30061359
18.

Therapeutic cancer vaccine: building the future from lessons of the past.

Tran T, Blanc C, Granier C, Saldmann A, Tanchot C, Tartour E.

Semin Immunopathol. 2019 Jan;41(1):69-85. doi: 10.1007/s00281-018-0691-z. Epub 2018 Jul 5. Review.

PMID:
29978248
19.

HPV RNA CISH score identifies two prognostic groups in a p16 positive oropharyngeal squamous cell carcinoma population.

Augustin J, Mandavit M, Outh-Gauer S, Grard O, Gasne C, Lépine C, Mirghani H, Hans S, Bonfils P, Denize T, Bruneval P, Bishop JA, Fontugne J, Péré H, Tartour E, Badoual C.

Mod Pathol. 2018 Nov;31(11):1645-1652. doi: 10.1038/s41379-018-0090-y. Epub 2018 Jun 20.

PMID:
29925856
20.

Evaluation of the efficacy of the 4 tests (p16 immunochemistry, polymerase chain reaction, DNA, and RNA in situ hybridization) to evaluate a human papillomavirus infection in head and neck cancers: a cohort of 348 French squamous cell carcinomas.

Augustin J, Outh-Gauer S, Mandavit M, Gasne C, Grard O, Denize T, Nervo M, Mirghani H, Laccourreye O, Bonfils P, Bruneval P, Veyer D, Péré H, Tartour E, Badoual C.

Hum Pathol. 2018 Aug;78:63-71. doi: 10.1016/j.humpath.2018.04.006. Epub 2018 Apr 22.

PMID:
29684499
21.

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells.

Granier C, Vinatier E, Colin E, Mandavit M, Dariane C, Verkarre V, Biard L, El Zein R, Lesaffre C, Galy-Fauroux I, Roussel H, De Guillebon E, Blanc C, Saldmann A, Badoual C, Gey A, Tartour É.

J Vis Exp. 2018 Feb 8;(132). doi: 10.3791/56606.

PMID:
29553498
22.

Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians.

Outh-Gauer S, Alt M, Le Tourneau C, Augustin J, Broudin C, Gasne C, Denize T, Mirghani H, Fabre E, Ménard M, Scotte F, Tartour E, Badoual C.

Cancer Treat Rev. 2018 Apr;65:54-64. doi: 10.1016/j.ctrv.2018.02.008. Epub 2018 Mar 1. Review.

PMID:
29547766
23.

[Tim-3: a novel biomarker and therapeutic target in oncology].

Granier C, Gey A, Dariane C, Mejean A, Timsit MO, Blanc C, Verkarre V, Radulescu C, Fabre E, Vano Y, Oudard S, Badoual C, Tartour É.

Med Sci (Paris). 2018 Mar;34(3):231-237. doi: 10.1051/medsci/20183403011. Epub 2018 Mar 16. Review. French.

24.

Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction.

Menasché P, Vanneaux V, Hagège A, Bel A, Cholley B, Parouchev A, Cacciapuoti I, Al-Daccak R, Benhamouda N, Blons H, Agbulut O, Tosca L, Trouvin JH, Fabreguettes JR, Bellamy V, Charron D, Tartour E, Tachdjian G, Desnos M, Larghero J.

J Am Coll Cardiol. 2018 Jan 30;71(4):429-438. doi: 10.1016/j.jacc.2017.11.047.

25.

New therapeutic targets in the inflammatory microenvironment.

Tartour E.

ESMO Open. 2018 Jan 13;3(1):e000310. doi: 10.1136/esmoopen-2017-000310. eCollection 2018. No abstract available.

26.

[Anti-cancer vaccines: What future in anti-cancer immunotherapy strategies?]

Tartour E.

Biol Aujourdhui. 2018;212(3-4):69-76. doi: 10.1051/jbio/2019002. Epub 2019 Apr 11. Review. French.

PMID:
30973134
27.

Tissue-resident memory T cells play a key role in the efficacy of cancer vaccines.

Granier C, Blanc C, Karaki S, Tran T, Roussel H, Tartour E.

Oncoimmunology. 2017 Aug 8;6(11):e1358841. doi: 10.1080/2162402X.2017.1358841. eCollection 2017.

28.

Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.

Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, Saldmann A, Gey A, Oudard S, Tartour E.

ESMO Open. 2017 Jul 3;2(2):e000213. doi: 10.1136/esmoopen-2017-000213. eCollection 2017. Review.

29.

Synthetic melanin bound to subunit vaccine antigens significantly enhances CD8+ T-cell responses.

Carpentier AF, Geinguenaud F, Tran T, Sejalon F, Martin A, Motte L, Tartour E, Banissi C.

PLoS One. 2017 Jul 17;12(7):e0181403. doi: 10.1371/journal.pone.0181403. eCollection 2017.

30.

Induction of resident memory T cells enhances the efficacy of cancer vaccine.

Nizard M, Roussel H, Diniz MO, Karaki S, Tran T, Voron T, Dransart E, Sandoval F, Riquet M, Rance B, Marcheteau E, Fabre E, Mandavit M, Terme M, Blanc C, Escudie JB, Gibault L, Barthes FLP, Granier C, Ferreira LCS, Badoual C, Johannes L, Tartour E.

Nat Commun. 2017 May 24;8:15221. doi: 10.1038/ncomms15221.

31.

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.

Roussel H, De Guillebon E, Biard L, Mandavit M, Gibault L, Fabre E, Antoine M, Hofman P, Beau-Faller M, Blons H, Danel C, Barthes FLP, Gey A, Granier C, Wislez M, Laurent-Puig P, Oudard S, Bruneval P, Badoual C, Cadranel J, Tartour E.

Oncoimmunology. 2017 Feb 21;6(4):e1286437. doi: 10.1080/2162402X.2017.1286437. eCollection 2017.

32.

Immunomodulatory Activity of VEGF in Cancer.

Lapeyre-Prost A, Terme M, Pernot S, Pointet AL, Voron T, Tartour E, Taieb J.

Int Rev Cell Mol Biol. 2017;330:295-342. doi: 10.1016/bs.ircmb.2016.09.007. Epub 2016 Dec 26. Review.

PMID:
28215534
33.

[The "immune checkpoints", how does it work].

Granier C, Soumelis V, Mandavit M, Gibault L, Belazzoug R, de Guillebon E, Badoual C, Tartour E, Roussel H.

Ann Pathol. 2017 Feb;37(1):18-28. doi: 10.1016/j.annpat.2016.12.007. Epub 2017 Feb 1. French.

PMID:
28160999
34.

[Immunotherapy in uropathology].

Verkarre V, Roussel H, Granier C, Tartour E, Allory Y.

Ann Pathol. 2017 Feb;37(1):90-100. doi: 10.1016/j.annpat.2016.12.015. Epub 2017 Jan 19. Review. French.

PMID:
28111042
35.

[Current events in immunotherapy for upper aerodigestive tract cancer].

Outh-Gauer S, Le Tourneau C, Broudin C, Scotte F, Roussel H, Hans S, Mandavit M, Tartour E, Badoual C.

Ann Pathol. 2017 Feb;37(1):79-89. doi: 10.1016/j.annpat.2016.12.013. Epub 2017 Jan 19. Review. French.

PMID:
28111039
36.

Biomarqueurs prédictifs de réponse aux traitements bloquant les voies de costimulation inhibitrices.

Pagès F, Granier C, Kirilovsky A, Elsissy C, Tartour E.

Bull Cancer. 2016 Nov;103 Suppl 1:S151-S159. doi: 10.1016/S0007-4551(16)30373-3. Review. French.

PMID:
28057179
37.

Immunothérapie dans les cancers de la prostate.

Oudard S, Thibault C, Angelergues A, Tartour E, Timsit MO, Mejean A, Michel C, Vano Y.

Bull Cancer. 2016 Nov;103 Suppl 1:S144-S150. doi: 10.1016/S0007-4551(16)30372-1. French.

PMID:
28057178
38.

L’immunothérapie des cancers : de l’espoir à la réalité.

Pagès F, Bay JO, Tartour E.

Bull Cancer. 2016 Nov;103 Suppl 1:S119-S121. doi: 10.1016/S0007-4551(16)30367-8. French. No abstract available.

PMID:
28057173
39.

Sunitinib in kidney cancer: 10 years of experience and development.

Nassif E, Thibault C, Vano Y, Fournier L, Mauge L, Verkarre V, Timsit MO, Mejean A, Tartour E, Oudard S.

Expert Rev Anticancer Ther. 2017 Feb;17(2):129-142. doi: 10.1080/14737140.2017.1272415. Epub 2016 Dec 27. Review.

PMID:
27967249
40.

Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study.

Auvray M, Elaidi R, Ozguroglu M, Guven S, Gauthier H, Culine S, Caty A, Dujardin C, Auclin E, Thibaut C, Combe P, Tartour E, Oudard S.

Clin Genitourin Cancer. 2017 Jun;15(3):e469-e476. doi: 10.1016/j.clgc.2016.10.013. Epub 2016 Nov 16.

PMID:
27964892
41.

Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma.

Granier C, Dariane C, Combe P, Verkarre V, Urien S, Badoual C, Roussel H, Mandavit M, Ravel P, Sibony M, Biard L, Radulescu C, Vinatier E, Benhamouda N, Peyromaure M, Oudard S, Méjean A, Timsit MO, Gey A, Tartour E.

Cancer Res. 2017 Mar 1;77(5):1075-1082. doi: 10.1158/0008-5472.CAN-16-0274. Epub 2016 Nov 21.

42.

Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors.

Karaki S, Anson M, Tran T, Giusti D, Blanc C, Oudard S, Tartour E.

Vaccines (Basel). 2016 Nov 3;4(4). pii: E37. Review.

43.

Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2016 Jul 25;5(9):e1214790. eCollection 2016. Review.

44.

Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects.

Daillère R, Vétizou M, Waldschmitt N, Yamazaki T, Isnard C, Poirier-Colame V, Duong CPM, Flament C, Lepage P, Roberti MP, Routy B, Jacquelot N, Apetoh L, Becharef S, Rusakiewicz S, Langella P, Sokol H, Kroemer G, Enot D, Roux A, Eggermont A, Tartour E, Johannes L, Woerther PL, Chachaty E, Soria JC, Golden E, Formenti S, Plebanski M, Madondo M, Rosenstiel P, Raoult D, Cattoir V, Boneca IG, Chamaillard M, Zitvogel L.

Immunity. 2016 Oct 18;45(4):931-943. doi: 10.1016/j.immuni.2016.09.009. Epub 2016 Oct 4.

45.

In Silico Adjuvant Design and Validation.

Davies MN, Pere H, Bosschem I, Haesebrouck F, Flahou B, Tartour E, Flower DR, Tough DF, Bayry J.

Methods Mol Biol. 2017;1494:107-125.

PMID:
27718189
46.

Ligand-receptor dissociated expression explains high TSLP without prognostic impact in human primary head and neck squamous cell carcinoma.

Guillot-Delost M, Guilleré L, Berger F, Ventre A, Michea P, Sirven P, Pattarini L, Scholer-Dahirel A, Kebir FZ, Huerre M, Chouchane-Mlik O, Lappartient E, Rodriguez J, Jouffroy T, Klijanienko J, Nicolas A, Sastre-Garau X, Honorio S, Mosseri V, Le Peltier N, Sablin MP, Le Tourneau C, Tartour É, Badoual C, Soumelis V.

Oncoimmunology. 2016 Jun 7;5(7):e1179414. doi: 10.1080/2162402X.2016.1179414. eCollection 2016 Jul.

47.

Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles.

Macedo R, Rochefort J, Guillot-Delost M, Tanaka K, Le Moignic A, Noizat C, Baillou C, Mateo V, Carpentier AF, Tartour E, Bertolus C, Bellier B, Lescaille G, Lemoine FM.

Oncoimmunology. 2016 Jul 6;5(7):e1164363. doi: 10.1080/2162402X.2016.1164363. eCollection 2016 Jul.

48.

Engineered mesenchymal stem cells as vectors in a suicide gene therapy against preclinical murine models for solid tumors.

Amara I, Pramil E, Senamaud-Beaufort C, Devillers A, Macedo R, Lescaille G, Seguin J, Tartour E, Lemoine FM, Beaune P, de Waziers I.

J Control Release. 2016 Oct 10;239:82-91. doi: 10.1016/j.jconrel.2016.08.019. Epub 2016 Aug 23.

PMID:
27565211
49.

Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Buqué A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2016 Mar 10;5(6):e1149674. doi: 10.1080/2162402X.2016.1149674. eCollection 2016 Jun. Review.

50.

Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.

Laheurte C, Galaine J, Beziaud L, Dosset M, Kerzerho J, Jacquemard C, Gaugler B, Ferrand C, Dormoy A, Aubin F, Jacoulet P, Westeel V, Borg C, Tartour E, Godet Y, Maillère B, Adotévi O.

Oncoimmunology. 2016 Feb 18;5(5):e1137416. doi: 10.1080/2162402X.2015.1137416. eCollection 2016 May.

Supplemental Content

Loading ...
Support Center